Risk of malignancy in patients with giant cell arteritis and polymyalgia rheumatica: A systematic review and meta-analysis
© 2014 Elsevier Inc. Objective: To investigate the association between giant cell arteritis (GCA)/polymyalgia rheumatica (PMR) and malignancy risk. Methods: We conducted a systematic review and meta-analysis of cohort studies that reported relative risk, hazard ratio, or standardized incidence ratio...
Saved in:
Main Authors: | , , , |
---|---|
Other Authors: | |
Format: | Article |
Published: |
2018
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/34709 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
id |
th-mahidol.34709 |
---|---|
record_format |
dspace |
spelling |
th-mahidol.347092018-11-09T09:56:25Z Risk of malignancy in patients with giant cell arteritis and polymyalgia rheumatica: A systematic review and meta-analysis Patompong Ungprasert Anawin Sanguankeo Sikarin Upala Eric L. Knight Columbia University, College of Physicians and Surgeons Mahidol University Medicine © 2014 Elsevier Inc. Objective: To investigate the association between giant cell arteritis (GCA)/polymyalgia rheumatica (PMR) and malignancy risk. Methods: We conducted a systematic review and meta-analysis of cohort studies that reported relative risk, hazard ratio, or standardized incidence ratio (SIRs) with 95% confidence comparing malignancy risk in patients with GCA/PMR versus non-GCA/PMR participants. Pooled risk ratios and 95% confidence intervals were calculated using a random-effect, generic inverse variance method. Result: A total of six studies were identified and included in our data analysis. The pooled risk ratio of malignancy in patients with GCA/PMR was 1.14 (95% CI: 1.05-1.22). The risk was higher in the first 6-12 months after diagnosis with the pooled risk ratio of 2.16 (95% CI: 1.85-2.53). However, when we performed a sensitivity analysis that excluded one study with a potential selection bias, the pooled risk ratio decreased and did not achieve statistical significance. Conclusion: Our study demonstrated a low but statistically significant increased malignancy risk among patients with GCA/PMR. However, when we excluded one study with potential selection bias, the new pooled risk ratio did not achieve statistical significance. 2018-11-09T02:56:25Z 2018-11-09T02:56:25Z 2014-01-01 Article Seminars in Arthritis and Rheumatism. Vol.44, No.3 (2014), 366-370 10.1016/j.semarthrit.2014.06.004 1532866X 00490172 2-s2.0-84919597136 https://repository.li.mahidol.ac.th/handle/123456789/34709 Mahidol University SCOPUS https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84919597136&origin=inward |
institution |
Mahidol University |
building |
Mahidol University Library |
continent |
Asia |
country |
Thailand Thailand |
content_provider |
Mahidol University Library |
collection |
Mahidol University Institutional Repository |
topic |
Medicine |
spellingShingle |
Medicine Patompong Ungprasert Anawin Sanguankeo Sikarin Upala Eric L. Knight Risk of malignancy in patients with giant cell arteritis and polymyalgia rheumatica: A systematic review and meta-analysis |
description |
© 2014 Elsevier Inc. Objective: To investigate the association between giant cell arteritis (GCA)/polymyalgia rheumatica (PMR) and malignancy risk. Methods: We conducted a systematic review and meta-analysis of cohort studies that reported relative risk, hazard ratio, or standardized incidence ratio (SIRs) with 95% confidence comparing malignancy risk in patients with GCA/PMR versus non-GCA/PMR participants. Pooled risk ratios and 95% confidence intervals were calculated using a random-effect, generic inverse variance method. Result: A total of six studies were identified and included in our data analysis. The pooled risk ratio of malignancy in patients with GCA/PMR was 1.14 (95% CI: 1.05-1.22). The risk was higher in the first 6-12 months after diagnosis with the pooled risk ratio of 2.16 (95% CI: 1.85-2.53). However, when we performed a sensitivity analysis that excluded one study with a potential selection bias, the pooled risk ratio decreased and did not achieve statistical significance. Conclusion: Our study demonstrated a low but statistically significant increased malignancy risk among patients with GCA/PMR. However, when we excluded one study with potential selection bias, the new pooled risk ratio did not achieve statistical significance. |
author2 |
Columbia University, College of Physicians and Surgeons |
author_facet |
Columbia University, College of Physicians and Surgeons Patompong Ungprasert Anawin Sanguankeo Sikarin Upala Eric L. Knight |
format |
Article |
author |
Patompong Ungprasert Anawin Sanguankeo Sikarin Upala Eric L. Knight |
author_sort |
Patompong Ungprasert |
title |
Risk of malignancy in patients with giant cell arteritis and polymyalgia rheumatica: A systematic review and meta-analysis |
title_short |
Risk of malignancy in patients with giant cell arteritis and polymyalgia rheumatica: A systematic review and meta-analysis |
title_full |
Risk of malignancy in patients with giant cell arteritis and polymyalgia rheumatica: A systematic review and meta-analysis |
title_fullStr |
Risk of malignancy in patients with giant cell arteritis and polymyalgia rheumatica: A systematic review and meta-analysis |
title_full_unstemmed |
Risk of malignancy in patients with giant cell arteritis and polymyalgia rheumatica: A systematic review and meta-analysis |
title_sort |
risk of malignancy in patients with giant cell arteritis and polymyalgia rheumatica: a systematic review and meta-analysis |
publishDate |
2018 |
url |
https://repository.li.mahidol.ac.th/handle/123456789/34709 |
_version_ |
1763498189341589504 |